Previously submitted to: JMIR mHealth and uHealth (no longer under consideration since Oct 08, 2021)
Date Submitted: Aug 22, 2020
Open Peer Review Period: Aug 22, 2020 - Aug 30, 2020
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
What are the implications of standards to ensure safe use of dermatological health apps?
ABSTRACT
Background:
Dermatological health applications can address a range of pathologies from melanoma to eczema and have the potential to significantly impact the health of the user. This paper details a systematic review of standards addressing dermatological health apps and their implication on the safe use of such apps.
Objective:
To survey the literature to ascertain the state of evidence to address this review’s primary research question: “What are the implications of standards to ensure safe use of dermatological health apps?”
Methods:
Six databases were systematically searched for records relevant to the questions using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist was used to analyse records when applicable, and when not a standardised checklist was used. Database searches identified 2193 records, of which 67 records were ultimately included for analysis.
Results:
A total of 67 records were identified, and these could be organised into 6 themes. These 6 themes included studies investigating the accuracy of apps, general standards, articles, reviews of current dermatological apps, recommendations and reviews of mobile medical apps and standards.
Conclusions:
This systematic review showed that there is a large variance in the quality of dermatological apps available to the public and the standards and guidelines currently in place are insufficient in eliminating all inaccuracies. Standards and guidelines surrounding the algorithms often used in dermatological apps as well as guidance on effective use of existing apps could potentially allow for more effective dermatological health apps.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.